To be considered, you must meet the following requirements: 1) The poster must result from research done as a student and be in the area of disease ecology. 2) If there are multiple authors, the ...

SPY001 is a novel, half-life extended α4β7 antibody in development for the treatment of Inflammatory Bowel Disease (IBD) SPY001 pharmacokinetic (PK) data up to eight months continues to support ...

Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will be sharing oral and poster ...

(NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting ...

Gain Therapeutics is presenting their lead drug candidate, GT-02287, for Parkinson's disease at the IAPRD conference. When is the oral poster presentation scheduled? The oral poster presentation ...